{
    "nctId": "NCT00885612",
    "briefTitle": "10 Year Coronary Heart Disease (CHD) Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer (EBC) Patients Taking Aromatase Inhibitors (AI)",
    "officialTitle": "10-year CHD Risk Evaluation and Its Treatment Pattern Analysis in Postmenopausal Early Breast Cancer Patients Taking Aromatase Inhibitors",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 1114,
    "primaryOutcomeMeasure": "The primary objective of this study is to define 10-year CHD risk according to Framingham risk score in postmenopausal early breast cancer patients who are taking aromatase inhibitors as an adjuvant treatment.",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Early Breast Cancer patients\n* Postmenopausal Status\n* patients taking Aromatase Inhibitor as adjuvant treatment no longer than 6 months\n\nExclusion Criteria:\n\n* Advanced Breast Cancer patients(stage iii, iv)\n* Patients who are hard to be analysed by limitation of chart record according to investigators discretion\n* patients who already have been registered in this study",
    "sex": "FEMALE",
    "minimumAge": "50 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}